The dataset (Elsafty_Reports_of_Myeloid_Neoplasms_2024) consists of 14,441 comprehensive clinicopathologic correlations (CPCs) for myeloid neoplasms (MN) with corresponding laboratory results. Specialized online platform utilizing these laboratory results automatically generated the diagnostic and prognostic CPCs. These results include complete blood counts (CBC), peripheral blood smear (PBS) findings, blast/promyelocyte count with dysplasia screening by flow cytometry, and molecular results by NGS/PCR. Two Hematopathologists, who performed the CBC and PBS review, collected their 10,794 real-world reports of cases served in Egypt with molecular studies performed in the USA and Europe. These newly-diagnosed cases included 243 chronic myeloid leukemia (CML) cases with 257 mutations/aberrations; 4,567 non-CML MN cases with 7,883 Tiers I/II mutations/aberrations, amino acid changes, and allele frequencies; and 5,984 benign/inconclusive cases with negative NGS for myeloid mutations/aberrations in 66 DNA/RNA genes. Additionally, there are 3,647 CPCs with synthetic genomics simulating all new/follow-up CML cases and complex/rare non-CML MN cases. Stringent validation by 51 international professors/consultants/specialists from multiple medical centres confirmed 100% medical and clerical accuracy, referencing the WHO 5th edition and relevant esteemed publications.